Inventor · disambiguated record
Brian Bettencourt
Also filed as: BETTENCOURT BRIAN · BETTENCOURT BRIAN L · BETTENCOURT BRIAN R · BETTENCOURT BRIAN RICHARD
81 granted patents·70 pending applications·506 citations·filing 2004–2025
99Inventor score
Files withALNYLAM PHARMACEUTICALS INC107ARROWHEAD PHARMACEUTICALS INC5TAKEDA PHARMACEUTICALS USA INC5TRIPLET THERAPEUTICS INC5BETTENCOURT BRIAN3
Top patents by PatentIndex Score
151 records- 0199US11525138B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Dec 13, 2022·7 cites·28 claims
- 0299US11130953B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Sep 28, 2021·8 cites·30 claims
- 0398US11866709B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 9, 2024·3 cites·29 claims
- 0498US11840692B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·3 cites·29 claims
- 0598US11834662B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·3 cites·29 claims
- 0698US11332743B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted May 17, 2022·6 cites·26 claims
- 0798US11306315B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 0898US11306314B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 0998US11306316B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 1098US9771591B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Sep 26, 2017·22 cites·34 claims
- 1198US9322018B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Apr 26, 2016·36 cites·41 claims
- 1298US9249415B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·24 cites·30 claims
- 1397US10557139B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 11, 2020·15 cites·20 claims
- 1497US10550390B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 4, 2020·15 cites·20 claims
- 1597US10337010B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Jul 2, 2019·17 cites·31 claims
- 1696US11873491B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 16, 2024·2 cites·32 claims
- 1796US10988768B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Apr 27, 2021·3 cites·21 claims
- 1896US10934545B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·6 cites·25 claims
- 1996US9879261B2Serpina1 siRNAs: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jan 30, 2018·10 cites·7 claims
- 2096US9850488B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Dec 26, 2017·11 cites·62 claims
- 2196US9701963B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Jul 11, 2017·9 cites·32 claims
- 2296US9127274B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS·Filed 2013·Granted Sep 8, 2015·51 cites·62 claims
- 2395US9783806B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Oct 10, 2017·16 cites·30 claims
- 2495US9133461B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Sep 15, 2015·19 cites·58 claims
- 2594US11419942B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 23, 2022·2 cites·55 claims
- 2694US10913950B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Feb 9, 2021·5 cites·20 claims
- 2794US10238749B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 26, 2019·12 cites·44 claims
- 2893US11186842B2Complement component iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 30, 2021·4 cites·18 claims
- 2993US11079379B2Methods of treating transthyretin (TTR) mediated amyloidosisALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Aug 3, 2021·4 cites·11 claims
- 3093US10465194B2Complement component iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Nov 5, 2019·11 cites·11 claims
- 3193US9574192B2Serapina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Feb 21, 2017·14 cites·36 claims
- 3292US12467051B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Nov 11, 2025·0 cites·13 claims
- 3392US10814007B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 27, 2020·3 cites·15 claims
- 3491US11198876B2Compositions and methods for inhibiting expression of TMPRSS6 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Dec 14, 2021·3 cites·23 claims
- 3591US11136582B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 5, 2021·4 cites·26 claims
- 3691US10745704B2Compositions and methods for inhibiting expression of CD274/PD-L1 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Aug 18, 2020·3 cites·13 claims
- 3791US9376680B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 28, 2016·7 cites·55 claims
- 3891US9228188B2Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expressionBETTENCOURT BRIAN·Filed 2012·Granted Jan 5, 2016·8 cites·22 claims
- 3991US8507663B2Compositions and methods for inhibiting expression of CD274/PD-L1 geneDEFOUGEROLLES ANTONIN·Filed 2011·Granted Aug 13, 2013·22 cites·16 claims
- 4090US11162098B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 2, 2021·2 cites·19 claims
- 4190US10935917B2Serpina1 siRNAs: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·2 cites·29 claims
- 4290US10030244B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Jul 24, 2018·6 cites·28 claims
- 4390US9725718B2Compositions and methods for inhibition of expression of protein C (PROC) genesALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 8, 2017·3 cites·33 claims
- 4490US9631193B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Apr 25, 2017·8 cites·45 claims
- 4589US9422562B2Compositions and methods for inhibiting expression of CD274/PD-L1 geneALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Aug 23, 2016·8 cites·13 claims
- 4689US2025064943A1ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4788US11253605B2Codon-optimized CFTR MRNATRANSLATE BIO INC·Filed 2018·Granted Feb 22, 2022·3 cites·14 claims
- 4888US2025034566A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4988US2024309387A1TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 5087US10400239B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 3, 2019·3 cites·51 claims
Showing the top 50 of 151 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Brian Bettencourt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →